The death toll of an outbreak linked to contaminated recalled eye drops have risen and more people have lost their vision, which has been distributed by Global Pharma, India’s leading pharmaceutical and biotechnology company.
Global Pharma according to its website, is a pharmaceutical company dedicated to ensuring the health and well-being of communities around the world. Our commitment to quality, innovation, and customer service has allowed our company to thrive.
For more than two decades, we have been providing a wide range of pharmaceutical formulations in several therapeutic forms to a variety of markets in Southeast Asia, Central America, LATAM, CIS, and Africa.
68 people across the U.S. are now known to have been infected by contaminated eyedrops… Leaving 3 people dead, 8 people blind, and 4 others needing their eyeballs removed according to CDC.
According to an update issued by the Centers for Disease Control and Prevention on Tuesday, the number of deaths has risen from one — which occurred in Washington state — to three.
What’s more, at least eight people have gone blind and four people have had their eyeballs surgically removed.
The CDC did not provide any information in its update about the affected patients including names, ages, sexes, or where they live.
More than 10 different brands of artificial tears have been recalled. Most cases have been linked to EzriCare and Delsam Pharma eye drops, made by India-based Global Pharma Healthcare.
According to the CDC, the eye drops were contaminated with an antibiotic-resistant form of Pseudomonas aeruginosa, an aggressive bacterium.
This scanning electron microscope image made available by the Centers for Disease Control and Prevention shows rod-shaped Pseudomonas aeruginosa bacteria.
Pseudomonas are a type of bacteria found in the environment, with P. aeruginosa being the most common to cause infections in humans.
The infection is common health care settings and spreads from improper hygiene either due to unclean hands or medical equipment and surfaces not being properly cleaned.
P. aeruginosa is resistant to multiple types of antibiotics and has caused about 32,600 infections among U.S. hospitalized patients and an estimated 2,700 deaths, according to the CDC.
The strain that has been linked to the outbreak, however, had never been reported in the United States before, the CDC stated in its update.
As of March 14, 68 people across 16 states have been infected with P. aeruginosa. Of those cases, 37 have been linked to four health care clusters.
“Testing of opened product identified the outbreak strain in bottles of EzriCare Artificial Tears that were obtained from two states,” the CDC told ABC News in a statement. “Testing of unopened product to evaluate for intrinsic contamination is ongoing by [the U.S. Food and Drug Administration].”
Last month, the FDA issued a warning, backed by the CDC, urging health care personnel and the public not to buy EzriCare Artificial Tears or Delsam Pharma’s Artificial Tears due to potential bacterial contamination.
After the warning, Global Pharma Healthcare issued a voluntary recall of both products, notifying distributors and advising wholesalers, retailers and customers who have the products to stop usage.
Not long after, the FDA also recommended that Global Pharma recall Delsam Pharma’s Artificial Eye Ointment, which the company agreed to. So far, no reports of infections have been linked to this product.
The CDC has warned anyone with symptoms of an eye infection who used EzriCare or Delsam Pharma eye drops to seek medical care immediately.
Such symptoms include yellow, green, or clear discharge from the eye; eye pain or discomfort; red eyes or eyelids; feeling of something in the eye; increased sensitivity to light; and blurry vision.
“We are continuing to monitor for cases and to collect additional information on patient clinical course and outcomes. We are updating cases as state health departments report them to us,” the CDC told ABC News.
According to the Company:
Global Pharma Healthcare Issues Voluntary Nationwide Recall of Artificial Tears Lubricant Eye
Drops Due to Possible Contamination
Company Contacts:
Aru Pharma/EzriCare, LLC: Phone Number 1-516-715-5181
Delsam Pharma: Mr. Kuppusamy Arumugam
Phone Number 1-866-826-1306
FOR IMMEDIATE RELEASE – February 2, 2023 – Global Pharma Healthcare is
voluntarily recalling all lots within expiry of their Artificial Tears Lubricant Eye Drops,
distributed by /EzriCare, LLC- and Delsam Pharma, to the consumer level, due to possible
contamination. The Centers for Disease Control and Prevention (CDC) alerted FDA to an
investigation of a multi-state cluster of Verona Integron-mediated Metallo-β-lactamase (VIM)-
and Guiana-Extended Spectrum-β-Lactamase (GES)- producing carbapenem-resistant
Pseudomonas aeruginosa (VIM-GES-CRPA) infections possibly associated with the use of the
artificial tears manufactured by Global Pharma Healthcare. To date, there are 55 reports of
adverse events including eye infections, permanent loss of vision, and a death with a bloodstream
infection.
Risk Statement: Use of contaminated artificial tears can result in the risk of eye infections that
could result in blindness.
Artificial Tears (carboxymethylcellulose sodium) Lubricant Eye Drops, 10 mg in 1 mL, ½ fl oz
(15 ml) bottle are used as a protectant against further irritation or to relieve dryness of the eye
for the temporary relief of discomfort due to minor irritations of the eye, or to exposure to wind
or sun. The product is packaged in a bottle with a safety seal and are placed in a carton box
Ezricare NDC 79503-0101-15, UPC 3 79503 10115 7; Delsam Pharma’s NDC 72570-121-15,
UPC -3 72570 12115 8. I
t can be identified by the photos below. The product was distributed
Nationwide in the USA over the Internet.